Drug
VOB-560 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
3 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 2
Institut de Recherches Internationales Servier (2) · Novartis Pharmaceuticals (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses VOB-560 is read from its arms, and is right about nine times in ten.
Testing it · 3
- Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid LeukemiaCompletedPhase 1/2Institut de Recherches Internationales ServierNCT04742101Written as S65487 and azacitidine
- VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)TerminatedPhase 1Novartis PharmaceuticalsNCT04702425Written as VOB560
- Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic LeukemiaTerminatedPhase 1Institut de Recherches Internationales ServierNCT03755154Written as S65487- initial scheme
Codes
What other systems call VOB-560 · ClinicalTrials.gg INT018078
- UNII (FDA) U4AQZ7WS5XVOB-560One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | U4AQZ7WS5X | VOB-560 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.